Stockscreener 앱 받기
9.74
2.70%
-0.27
시간 외 거래:
9.72
-0.02
-0.21%
Novavax Inc 주식(NVAX)의 최신 뉴스
Novavax, Inc. (NASDAQ:NVAX) Given Average Rating of "Hold" by Brokerages - MarketBeat
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Is trending stock Novavax, Inc. (NVAX) a buy now? - MSN
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax (NASDAQ:NVAX) Trading 7.6% HigherShould You Buy? - MarketBeat
Here’s What You Should Understand Besides the Reason Novavax, Inc. (NVAX) is Gaining Attention - Bitget
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock - Yahoo Finance
DC InnoNovavax cancels Covid-19 vaccine contract | Oxiwear is going global - The Business Journals
Novavax Inc. stock underperforms Monday when compared to competitors - MarketWatch
Farallon Capital Management LLC Purchases 764,000 Shares of Novavax, Inc. $NVAX - MarketBeat
Nuvaxovid (Novavax) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F - Yahoo Finance
How (NVAX) Movements Inform Risk Allocation Models - Stock Traders Daily
FDA to Mandate Placebo-Controlled Trials for New Vaccines - MSN
Jefferies Maintains Buy on Novavax, Inc. (NVAX) March 2026 - Meyka
BTIG Maintains a Buy Rating on Novavax (NVAX), Sets a $19 PT - MSN
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Novavax (NVAX) director John W. Shiver converts 7,947 RSUs into stock - Stock Titan
Jefferies reiterates Buy on Novavax stock, cites adjuvant platform By Investing.com - Investing.com India
Jefferies reiterates Buy on Novavax stock, cites adjuvant platform - Investing.com
Assessing Novavax (NVAX) Valuation After Strong 2025 Results And Return To Profitability - simplywall.st
Novavax (NASDAQ:NVAX) Share Price Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Novavax Q4 earnings preview: Wall Street expects wider losses amid diversification efforts - MSN
Novavax (NVAX) Gains Momentum with Sanofi Deal and Analyst Endorsement - MSN
Novavax stock hits over 1-year high: Is Sanofi’s flu-COVID shot the post-pandemic growth driver? - MSN
The 7 Most Hated Stocks on Wall Street Today | Investing - Money/ US News
NVAX: Pivot to platform partnerships and innovation drives growth, with profitability targeted by 2028 - TradingView
Novavax (NVAX) EVP granted 139,500 non-statutory stock options - Stock Titan
Novavax Inc. (NVAX) legal chief updates 152,000-share stock option terms - Stock Titan
Novavax (NVAX) EVP granted 177,500 options with revised terms - Stock Titan
Therapeutics Companies Exceed Q4 2025 Revenue Estimates, Led by Novavax and AmgenNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Novavax Retail Traders Rally In Defense After RFK Jr.'s COVID-19 Vaccine Skepticism Sends Stock Tumbling - MSN
NOVAVAX INC (NASDAQ:NVAX) Screens as a Minervini-Style High-Growth Momentum Candidate - ChartMill
How Investors Are Reacting To Novavax (NVAX) Swinging From Losses To Profits On Vaccine Revenue - simplywall.st
Update Recap: Can Novavax Inc. stock maintain growth trajectory2025 Stock Rankings & High Conviction Trade Alerts - Naître et grandir
NVAX Stock Rises Pre-Market As Pfizer Licenses Its Vaccine Technology - Stocktwits
Assessing Novavax (NVAX) Valuation After Strong Earnings Beat And Return To Profitability - simplywall.st
Novavax (NVAX) CFO reports RSU vesting and 20,850 shares withheld for taxes - Stock Titan
Novavax (NVAX) EVP Elaine O'Hara nets shares from RSU vesting and tax withholding - Stock Titan
Novavax (NVAX) legal chief logs RSU vesting and tax share withholding - Stock Titan
[Form 4] NOVAVAX INC Insider Trading Activity - Stock Titan
Novavax, Inc. $NVAX Stock Position Lowered by Vanguard Group Inc. - MarketBeat
Novavax at TD Cowen Conference: Strategic Shift to Adjuvant Licensing - Investing.com
Novavax (NVAX) EVP Elaine O'Hara receives major RSU and option grants - Stock Titan
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
NVAX: Pivoting to a partnership-driven model, the company targets profitability by 2028 with robust pipeline and deals - TradingView
Is Novavax, Inc. (NVAX) a Good Buy at the Moment? - Bitget
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now? - Yahoo Finance
NVAX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash - Stocktwits
Trading Systems Reacting to (NVAX) Volatility - Stock Traders Daily
Sanofi Takes Charge of Novavax COVID Vaccine, Mixed Financial Projections Ahead - StocksToTrade
Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue - Stocktwits
Novavax, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:NVAX) 2026-02-28 - Seeking Alpha
Novavax Stock Faces Uncertain Future Amid Low Revenue Guidance - StocksToTrade
Assessing Novavax (NVAX) Valuation After Surprise Q4 Profitability And New Pfizer Licensing Deal - Yahoo Finance
How The Novavax (NVAX) Story Is Shifting Toward Licensing Income And COVID Recalibration - Yahoo Finance
Novavax (NASDAQ:NVAX) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Novavax (NASDAQ:NVAX) Trading Down 9.8%Here's What Happened - MarketBeat
Why Novavax (NVAX) Shares Are Falling Today - Finviz
Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof (NASDAQ:NVAX) - Seeking Alpha
Novavax (NASDAQ:NVAX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Novavax, Inc. (NASDAQ:NVAX) Q4 2025 Earnings Call Transcript - Insider Monkey
Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates - Nasdaq
H.C. Wainwright raises Novavax stock price target on guidance beat - Investing.com
1.20%
0.06%
자본화:
|
볼륨(24시간):